Business Segments · Capital expenditures, gross
Biotechnology — Capital expenditures, gross
Danaher Biotechnology — Capital expenditures, gross decreased by 44.3% to $64M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.0%, from $81M to $64M. Over 4 years (FY 2021 to FY 2025), Biotechnology — Capital expenditures, gross shows relatively stable performance with a -1.0% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026Apr 21, 2026
Rolls up toProperty, plant, and equipment additions
How to read this metric
Higher spending suggests investment in future growth, while lower spending may indicate a focus on cash preservation.
Detailed definition
The total cash outflow for the acquisition or maintenance of long-term physical assets within the biotechnology segment....
Peer comparison
Standard capital investment metric across manufacturing and life science peers.
Metric ID:
dhr_segment_biotechnology_capital_expenditures_grossHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $96.25M | $96.25M | $96.25M | $101.25M | $101.25M | $101.25M | $101.25M | $104.25M | $104.25M | $104.25M | $104.25M | $102M | $111M | $117M | $117M | $81M | $80M | $94M | $115M | $64M |
| QoQ Change | — | +0.0% | +0.0% | +5.2% | +0.0% | +0.0% | +0.0% | +3.0% | +0.0% | +0.0% | +0.0% | -2.2% | +8.8% | +5.4% | +0.0% | -30.8% | -1.2% | +17.5% | +22.3% | -44.3% |
| YoY Change | — | — | — | — | +5.2% | +5.2% | +5.2% | +3.0% | +3.0% | +3.0% | +3.0% | -2.2% | +6.5% | +12.2% | +12.2% | -20.6% | -27.9% | -19.7% | -1.7% | -21.0% |
Range$64M – $117M
CAGR-8.2%
Avg YoY Growth-2.2%
Median YoY Growth+3.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology — capital expenditures, gross?
- Danaher (DHR) reported biotechnology — capital expenditures, gross of $64M in Q1 2026.
- How has Danaher's biotechnology — capital expenditures, gross changed year-over-year?
- Danaher's biotechnology — capital expenditures, gross decreased by 21.0% year-over-year, from $81M to $64M.
- What is the long-term trend for Danaher's biotechnology — capital expenditures, gross?
- Over 4 years (2021 to 2025), Danaher's biotechnology — capital expenditures, gross has grown at a -1.0% compound annual growth rate (CAGR), from $385M to $370M.
- What does biotechnology — capital expenditures, gross mean?
- Total spending on physical assets and infrastructure for the biotechnology segment.